Advances in Autism Conference 2019


Our 23rd annual Advances in Autism Conference, established in 1996, brings together academic, parent and community groups to participate in thoughtful and informative presentations. The goals of the conference are to teach attendees about recent advances in understanding autism – the causes, brain development, and current treatments.

This year, the Advances in Autism Conference will focus on Drug Discovery and Development in autism and other neurodevelopmental disorders.

Drugs are developed to improve quality of life. The drug discovery and development process is exciting and extremely challenging. To ensure safety and effectiveness, bringing a new drug to market for patients takes many years.

From determining genetic factors to target for treatment – to completing pre-clinical research and clinical trials - there are a variety of stakeholders who have key roles in this process.

The speakers at the Conference will represent biotech, pharma, academia and family foundations – who will explain the many facets of the drug discovery and development process.

Sponsorship and Tickets

If you are interested in sponsorship opportunities or would like to purchase tickets, please visit our Eventbrite page or contact Sarah Lynch by email or phone 212-241-0349.


Joseph D. Buxbaum, PhD - Genetics and Neurodevelopmental Disorders
Director, Seaver Autism Center for Research and Treatment
Vice Chair for Research, Seaver Autism Center Professor and Deputy Chair, Department of Psychiatry, Mount Sinai

Stormy J. Chamberlain, PhD - Development of Targeted Therapeutics for Angelman Syndrome
Associate Professor, Genetics and Genome Sciences at University of Connecticut Health Center

Omar Khwaja, MD, PhD - Novel Therapeutic Modalities for Neurodevelopmental Disorders
Chief Medical Officer and Head of Research and Development at Voyager Therapeutics

Ana Kostic, PhD - Drug Discovery and Development at the Seaver Autism Center
Director, Drug Discovery and Development, Seaver Autism Center for Research and Treatment
Associate Professor, Psychiatry, Mount Sinai

Christine McSherry, RN - One Parent’s Journey
Founder, Jett Foundation

William J. Polvino, MD - What does it take to make a medicine? The Process and Perspectives from an Optimist
CEO, Bridge Medicines

Jordi Serrats, PhD - Patient-focused Approaches to Drug Discovery in Neurodevelopmental Disorders
Associate Director; Neuroscience Drug Discovery Unit at Takeda

Tech Innovation in Autism Panel

Bharat Ramani
President at Uplift Innovation, Inc

Christopher Dudick
CEO, Silas Solutions

Julie LeMoine
PhD Candidate in Applied AR for Autism, UCD School of MME, SMARTlab
Co-founder, UMass Medical School, Shriver InovaXR Lab

Jack Vanden Heuvel, PhD
Professor of Molecular Toxicology, Penn State University
Chief Scientific Officer, Beautiful BioSolutions and INDIGO Biosciences, Inc.